Literature DB >> 11704035

Ipsilateral recurrence of nonarteritic anterior ischemic optic neuropathy.

S S Hayreh1, P A Podhajsky, B Zimmerman.   

Abstract

PURPOSE: To report the prevalence of recurrence of nonarteritic anterior ischemic optic neuropathy (NA-AION) in the same eye and possible contributing risk factors.
DESIGN: Cohort study.
SETTING: Institutional. STUDY POPULATION: The study includes 594 consecutive patients (829 eyes) with a diagnosis of NA-AION and follow-up of at least two months after the onset of NA-AION, examined in the Ocular Vascular Clinic since 1973. Simple progression of visual loss during an episode of NA-AION was not considered a fresh episode. INTERVENTION OR OBSERVATION PROCEDURES: Every patient had ophthalmic evaluation, including visual acuity, visual fields with a Goldmann perimeter, intraocular pressure, and slit lamp and ophthalmoscopic evaluation at initial visit and at each follow-up visit. The patients also had systemic evaluation; some patients had echocardiography (166 patients) and 24-hour ambulatory blood pressure (BP) monitoring-the latter was investigated in 80 patients (17 with and 63 without recurrence of NA-AION) who consented to participate in this study which was started in 1989. While optic disk edema was present, the patients were followed every 2 to 3 weeks. Once the optic disk edema resolved, they were followed up after 3 months, 6 months, and then at yearly intervals unless they had some new visual complaint. MAIN OUTCOME MEASURES: Prevalence of a fresh episode of NA-AION in the same eye, and comparison of ocular and systemic risk factors between patients with and without recurrence of NA-AION in the same eye.
RESULTS: Of the 594 patients (829 eyes) in the study, recurrence of NA-AION in the same eye occurred in 45 patients (53 eyes) with a median follow-up of 3.1 years (range 2 months to 30.5 years) from the first onset of NA-AION. The Kaplan-Meier survival curve showed cumulative percentage of recurrence of NA-AION from first episode to second episode at three months 1.0%+/-0.4%(SE), at 6 months 2.7%+/-0.7%, at one year 4.1%+/-0.9%, and 2 years 5.8%+/-1.1%. There was no significant association between recurrence of NA-AION and the systemic conditions that were examined, except for nocturnal arterial hypotension. Overall patients with a recurrence of NA-AION had a significantly lower mean nighttime minimum diastolic BP (P =.003) and greater mean percentage drop during sleep in diastolic BP (P =.011) than those with no recurrence of NA-AION; all other measures of nocturnal hypotension were not significantly predictive.
CONCLUSIONS: Recurrence of NA-AION in the same eye is uncommon (6.4%). Our study indicates that nocturnal diastolic arterial hypotension may be a risk factor; however, since this is a multifactorial disease, other so far unknown risk factors may also play a role. The role of various risk factors which may contribute to the recurrence of NA-AION is discussed.

Entities:  

Mesh:

Year:  2001        PMID: 11704035     DOI: 10.1016/s0002-9394(01)01192-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  20 in total

1.  Sudden loss of vision in a patient with significant ipsilateral internal carotid disease.

Authors:  Farhad Huwez; Udayaraj Umasankar; Edward Casswell; Jay Menon; Narasimha Gadi
Journal:  BMJ Case Rep       Date:  2011-12-05

2.  Non-arteritic anterior ischemic optic neuropathy versus cerebral ischemic stroke.

Authors:  Sohan Singh Hayreh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-21       Impact factor: 3.117

3.  Sequential nonarteritic anterior ischemic optic neuropathy in patient on chronic hemodialysis.

Authors:  Ari Shemesh; Edward Margolin
Journal:  CEN Case Rep       Date:  2018-11-21

Review 4.  Ischemic optic neuropathies - where are we now?

Authors:  Sohan Singh Hayreh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-07-03       Impact factor: 3.117

5.  Computerized expert system for evaluation of automated visual fields from the Ischemic Optic Neuropathy Decompression Trial: methods, baseline fields, and six-month longitudinal follow-up.

Authors:  Steven E Feldon
Journal:  Trans Am Ophthalmol Soc       Date:  2004

Review 6.  Treatment of nonarteritic anterior ischemic optic neuropathy.

Authors:  Edward J Atkins; Beau B Bruce; Nancy J Newman; Valérie Biousse
Journal:  Surv Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 6.048

7.  Clinical approach to optic neuropathies.

Authors:  Raed Behbehani
Journal:  Clin Ophthalmol       Date:  2007-09

8.  Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy.

Authors:  N R Miller; A C Arnold
Journal:  Eye (Lond)       Date:  2014-07-04       Impact factor: 3.775

9.  Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: a prospective trial.

Authors:  D B Rootman; H S Gill; E A Margolin
Journal:  Eye (Lond)       Date:  2013-02-01       Impact factor: 3.775

10.  A new characterization for nonarteritic anterior ischemic optic neuropathy.

Authors:  Aipeng Li; Lin Li; Miyang Li; Xiaoru Shi
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.